Management of Ventricular Arrhythmias: Detection, Drugs, and Devices
OBJECTIVE To review evaluation and treatment of patients with ventricular arrhythmias, based on recent studies, with an emphasis on randomized controlled trials. DATA SOURCES MEDLINE search of English-language publications of ventricular arrhythmias and their references from 1966 through April 27, 1...
Gespeichert in:
Veröffentlicht in: | JAMA : the journal of the American Medical Association 1999-01, Vol.281 (2), p.172-179 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | OBJECTIVE To review evaluation and treatment of patients with
ventricular arrhythmias, based on recent studies, with an emphasis on
randomized controlled trials. DATA SOURCES MEDLINE search of English-language publications of
ventricular arrhythmias and their references from 1966 through April
27, 1998. References to articles were also scanned to broaden the
search. STUDY SELECTION Randomized controlled trials and all large
nonrandomized trials of arrhythmias and arrhythmia therapy were
reviewed. In addition, studies that led to changes in approach to
patients with arrhythmias were reviewed. DATA EXTRACTION We reviewed articles jointly for pertinent studies
and information. DATA SYNTHESIS The goals of treatment of the patient with
ventricular arrhythmias are to suppress symptoms and prevent a fatal
event. The steps in providing such therapy include defining the cardiac
anatomy, assessing arrhythmia risk through noninvasive or invasive
testing, and prescribing treatment based on these results. Patients may
be separated into high- and low-risk groups to help identify
appropriate treatment. While low-risk groups may benefit from
reassurance or medications such as β-blockers or verapamil, high-risk
groups have been more difficult to treat. Recent randomized trials of
implantable cardioverter defibrillators for ventricular arrhythmias
suggest that they may provide better protection for high-risk patients
than do antiarrhythmic medications. CONCLUSIONS Treatment and understanding of risk from ventricular
arrhythmias have advanced substantially in recent years. Classifying
patients as being at high or low risk for fatal arrhythmias allows the
physician to identify appropriate treatments for the high-risk patient
without exposing the low-risk patient to unnecessary treatment-related
risks. |
---|---|
ISSN: | 0098-7484 1538-3598 |
DOI: | 10.1001/jama.281.2.172 |